The Memo: Tulyp Medical Brings Active Management to Limb Perfusion

Tulyp Medical is developing a pressure-guided limb-perfusion system designed to prevent procedure-associated acute limb ischemia by enabling clinicians to continuously monitor and regulate blood delivery to the affected limb. Initially focused on patients undergoing procedures involving femoral arterial access, including venoarterial extracorporeal membrane oxygenation (VA-ECMO) and other forms of mechanical circulatory support, Tulyp is seeking to shift limb perfusion from a passive, reactive practice to an actively managed therapy.

Origin Story

Tulyp Medical began with a problem its founders, a group of clinicians and cardiovascular-device experts, repeatedly encountered in practice. Femoral access devices introduced through the femoral artery can compromise blood flow to the lower limb, yet clinicians may not recognize inadequate perfusion until injury has already begun.

The founding premise was straightforward: rather than waiting for signs of a complication, clinicians should be able to actively measure and manage limb perfusion. That insight became the foundation for Tulyp’s pressure-guided limb-perfusion platform.

Steve joined the Paris-based company as CEO in 2026, bringing more than 25 years of experience across cardiovascular devices, mechanical circulatory support, and critical care. For Motes, who has spent much of his career helping build markets around technologies that change clinical practice, Tulyp presented a familiar kind of opportunity.

“I joined Tulyp because four things came together: a significant unmet clinical need, compelling clinician-founded technology, a deeply experienced cardiovascular team, and the opportunity to create an entirely new category of care,” Motes said. “Tulyp is that same kind of opportunity: moving limb perfusion from a passive, reactive approach to an actively managed therapy.”

While headquartered in France, Tulyp’s initial regulatory and commercial focus is the United States, where the company sees an opportunity to introduce the technology within high-acuity cardiovascular centers before pursuing broader international expansion.

The Current Landscape

Tulyp’s first clinical focus is patients undergoing procedures involving femoral arterial access, particularly VA-ECMO and other forms of mechanical circulatory support. In these procedures, the device occupying the femoral artery can reduce blood flow to the lower extremity and place the limb at risk of acute ischemia.

The consequences can be significant. “Acute limb ischemia can lead to additional interventions, prolonged hospitalization, permanent disability, amputation, and, in the most severe cases, death,” Motes explained. “Published literature has reported limb ischemia in roughly one in six patients receiving VA-ECMO, although incidence varies considerably by population, technique, and clinical definition.”

Yet the way clinicians address that risk remains largely passive.

Standard practice can involve placing a distal perfusion catheter connected to the arterial circuit to deliver blood downstream of the femoral access site. The limitation is that conventional systems do not continuously measure distal perfusion pressure or automatically adjust blood delivery to maintain a defined physiological target. Instead, clinicians rely on intermittent assessments and may be forced to respond after signs of inadequate perfusion have emerged.

For Tulyp, the opportunity is not simply to deliver blood to the limb. It is to make adequate perfusion something clinicians can continuously measure, target, and control.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-memo-tulyp-medical-brings-active-management-to-limb-perfusion